Toward Realizing the Full Potential of Registries in Interstitial Lung Disease
Open Access
- 1 December 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 17 (12) , 1534-1535
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and MethodsAnnals of the American Thoracic Society, 2020
- Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet Respiratory Medicine, 2020
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesNew England Journal of Medicine, 2019
- Patient Registries in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseNew England Journal of Medicine, 2019
- Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White PaperThe Lancet Respiratory Medicine, 2018
- The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis RegistryCanadian Respiratory Journal, 2016
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012